Antibiotice S.A., a prominent player in the pharmaceutical industry, is headquartered in Iaşi, Romania. Established in 1955, the company has evolved into a leading manufacturer of generic antibiotics and other essential medications, serving both domestic and international markets. With a strong focus on research and development, Antibiotice has achieved significant milestones, including the production of innovative formulations and a robust portfolio of over 200 products.
The company’s core offerings include injectable antibiotics, oral medications, and topical treatments, distinguished by their high quality and efficacy. Antibiotice is recognised for its commitment to sustainability and compliance with international standards, positioning itself as a trusted partner in healthcare. With a solid market presence in Europe and beyond, Antibiotice continues to contribute to global health through its dedication to pharmaceutical excellence.
+8 vs industry average
Antibiotice’s score of 46 is higher than 66% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Part of the Sustainability team at Antibiotice?
- Control how your company's emission story is told
- Respond to customers efficiently
- See who's viewing your profile
Industry Intensity
Pharmaceutical Preparation Manufacturing has below-average carbon intensity
Industry performance
The Pharmaceutical Preparation Manufacturing industry has reduced its overall emissions by 19% since 0
Emissions trajectory 2020 – 2028
Reported emissions
Scope 3 accounts for ••• of total emissions.
Antibiotice's reported carbon emissions
In 2025, Antibiotice reported total carbon emissions of approximately 101,133,000 kg CO2e. This figure includes Scope 1 emissions of about 10,116 kg CO2e, Scope 2 emissions of approximately 1,765,000 kg CO2e, and Scope 3 emissions of about 33,950 kg CO2e. The company has set an ambitious target to reduce its Scope 1 and Scope 2 emissions by 46% by 2030, using 2019 as the baseline year. This commitment reflects Antibiotice's dedication to addressing climate change and reducing its environmental impact within the pharmaceuticals, biotechnology, and life sciences sector. The company has consistently reported its emissions data, demonstrating transparency and accountability in its climate commitments. As part of its ongoing efforts, Antibiotice is focused on implementing strategies to achieve these reduction targets while maintaining operational efficiency.
Unlock detailed emission data
Access structured emission data, company specific factors and auditable source documents
Antibiotice’s Climate Goals (2030 & 2050)
2 goals2030
46% reduction in Scope 1
Reducerea cu 46% a emisiilor de GES pentru operațiunile proprii (Scope 1 și 2) până în 2030, având ca an de referință 2019.
2030
62% reduction in total GHG
Vs 2019 baseline. Validated by SBTi. Includes full supply chain.
2040
50% reduction in Scope 3 intensity
Across purchased goods and services and logistics.
See all 2 climate goals
Already have an account? Sign in now
Scope 3 top emissions categories
1 of 15 categories disclosedSee all scope 3 categories
Already have an account? Sign in now
Climate initiatives
Science Based Targets Initiative
Carbon Disclosure Project
The Climate Pledge
UN Global Compact Climate Champions initiative
RE 100
Climate Action 100
Emissions comparison with industry peers
View similar organisations
Antibiotice
Frequently asked questions
Common questions about Antibiotice’s sustainability data and climate commitments
Usage policy
You’re welcome to quote or reference data from this page, but please include a visible link back to this URL. Bulk collection, resale, or redistribution of data from multiple profiles is not permitted.
See our License Agreement for more details.
Where does DitchCarbondata come from?
Discover our data-driven methodology for measuring corporate climate action and benchmarking against industry peers
Learn moreCurious to see your top suppliers emissions?
Book a demo for a pilot project